ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 27, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 27, 2011
News
Abbott to Split into Medical-Products and Pharmaceuticals Companies
By Erik Greb
Abbott has unveiled a plan to separate into two publicly traded companies, one focusing on diversified medical products and the other on research-based pharmaceuticals.
EC Probes J&J and Novartis
By Stephanie Sutton
The European Commission has launched an antitrust investigation to examine whether contracts between Johnson & Johnson and Novartis were designed to delay the market entry of generic versions of Fentanyl in the Netherlands.
Merck, Sharpe, and Dohme Announces New Investments in Singapore
By Amy Ritter
Merck, Sharpe, and Dohme (MSD) and Singapore's Economic Development Board jointly announced plans for significant investments by MSD to improve its existing manufacturing facilities in Singapore, as well as for new manufacturing, marketing, and research activities.
Week of Oct. 24, 2011: Norwich Pharmaceuticals Increases Pilot-Scale Production Capabilities; Sanofi Appoints David Meeker as CEO of its Subsidiary Genzyme; and More
Norwich Pharmaceuticals Increases Pilot-Scale Production Capabilities; Sanofi Appoints David Meeker as CEO of its Subsidiary Genzyme; and More.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
18%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here